Myasthenia Gravis News

Our mission is to provide you with the latest science, research, and clinical updates on Myasthenia Gravis. We are a free online resource dedicated to serving the patient community.

International

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#810677

United States

#199642

Health/Health Conditions and Concerns

#510

Traffic sources

Monthly visitors

Articles

Battling 2 enemies: MG and the broken US healthcare system

4 days ago | myastheniagravisnews.com | Mark Harrington

Living with a rare disease is difficult enough, but in the United States, patients fight not only their illness, but also the healthcare system that’s supposed to help them. I was diagnosed with myasthenia gravis (MG) five years ago this month. Managing it requires specialized care, regular treatment, and access to breakthrough medications.
Tear-based antibody tests may help diagnose ocular MG: Study

1 week ago | myastheniagravisnews.com | Steve Bryson

Using tears to test for self-reactive antibodies to help diagnose ocular myasthenia gravis (OMG) is more accurate than using blood samples, according to a study that found nearly all patients who tested negative for these antibodies in the blood had a positive result in tears. “Tear-based testing offers a promising alternative for diagnosing [blood]-negative OMG cases,” the researchers wrote.
Juvenile myasthenia gravis in US may be more common than believed: Study

1 week ago | myastheniagravisnews.com | Marisa Wexler

A rare form of myasthenia gravis that manifests in childhood and adolescence called juvenile myasthenia gravis (JMG) affects roughly 30 out of every 1 million children in the U.S., and may be more common than previously thought, a study estimates. The study also found that JMG is more common among girls than boys, and in Black children over white children. “Understanding the incidence and prevalence of JMG is crucial for optimizing its management.
Enrollment opens in Phase 1 trial of NKX019 cell therapy in gMG

2 weeks ago | myastheniagravisnews.com | Steve Bryson

Enrollment is open in an investigator-initiated clinical trial to evaluate cell therapy NKX019 in people with myasthenia gravis (MG). Nkarta, the therapy’s developer, made the announcement in a company press release. Researchers at the University of California, Irvine, and the University of Kansas Medical Center are leading the open-label Phase 1 trial, which was given the go-ahead by the U.S. Food and Drug Administration late last year.
Kyverna planning to launch Phase 3 trial of KYV-101 in MG patients

3 weeks ago | myastheniagravisnews.com | Marisa Wexler

Kyverna Therapeutics is planning to launch a Phase 3 clinical trial testing its experimental cell therapy KYV-101 in people with myasthenia gravis (MG). The announcement follows an end-of-Phase 2 meeting between Kyverna and the U.S. Food and Drug Administration (FDA). According to the company, the FDA has aligned with plans to move KYV-101 into Phase 3 testing. Phase 3 trials are large studies designed to test if treatments are effective.
Vyvgart Hytrulo formulation available for generalized MG in US

1 month ago | myastheniagravisnews.com | Lindsey Shapiro

The recently approved prefilled syringe formulation of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that offers the possibility of self-administration is now available in the U.S. for eligible adults with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChRs).
Combined procedure better as myasthenic crisis treatment: Study

1 month ago | myastheniagravisnews.com | Margarida Maia

Plasma exchange — a procedure that clears antibodies, such as those that cause myasthenia gravis (MG), from the blood — may be a better myasthenic crisis treatment when used in combination with a procedure used to remove white blood cells, a study found. The combined procedure, called lymphoplasmapheresis, achieved better treatment outcomes than plasma exchange alone, in fewer treatment sessions. Both reduced the levels of MG-causing antibodies, but lymphoplasmapheresis appeared to perform better.
Enrollment complete in Phase 2 trial testing DNTH103 for gMG

1 month ago | myastheniagravisnews.com | Marisa Wexler

Enrollment is now complete for a Phase 2 clinical trial testing Dianthus Therapeutics‘ treatment candidate DNTH103 in people with generalized myasthenia gravis (gMG). According to the developer, the initial results from the global study, dubbed MAGIC (NCT06282159), are expected by early fall. MAGIC was launched early last year and is being conducted at 56 locations in North and South America, Europe, and Asia.
FDA approves J&J's nipocalimab, now Imaavy, to treat gMG

1 month ago | myastheniagravisnews.com | Lindsey Shapiro

The U.S. Food and Drug Administration (FDA) has approved nipocalimab as a treatment for adults and adolescents, ages 12 and older, with generalized myasthenia gravis (gMG) who have antibodies against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) proteins. The newly approved therapy will be sold by developer Johnson & Johnson (J&J) under the brand name Imaavy. This is the first regulatory approval for Imaavy in gMG.
Increased generalized MG severity tied to misdiagnosis, certain symptoms

1 month ago | myastheniagravisnews.com | Andrea Lobo

People with generalized myasthenia gravis (gMG) who were misdiagnosed at least once and who have certain disease symptoms are more likely to see an increase in disease severity, according to a recent study. Ocular symptoms and/or muscle aches after physical activity were significantly associated with a higher risk of gMG worsening. Patients who are employed patients and those with fatigue were more likely to see their disease severity reduce or stabilize.